Goldman Sachs initiates coverage on Crinetics stock with Neutral rating

Goldman Sachs initiated coverage on Crinetics Pharmaceuticals (CRNX) with a Neutral rating and a $36.00 price target, citing uncertainties surrounding the commercial viability and market penetration of its lead drug candidates. The firm highlighted limited risk-adjusted peak sales potential for acromegaly treatment paltusotine (under $600M) and competitive delays for CAH candidate atumelnant, despite its larger market opportunity. While CRNX maintains a strong financial position with robust liquidity and a cash runway into 2029, Goldman Sachs' outlook suggests near-term stock performance will be heavily dependent on these drug launches and competitor market dynamics, given few other pipeline catalysts.

Analysis

Goldman Sachs initiated coverage on Crinetics Pharmaceuticals (CRNX) with a Neutral rating and a $36.00 price target, introducing a cautious counterpoint to more bullish Street estimates. The firm's tempered outlook is rooted in specific concerns over the company's two lead assets. For paltusotine, an acromegaly treatment with a September 25 PDUFA date, Goldman forecasts risk-adjusted peak sales of less than $600 million by 2042, citing the limited size of the addressable patient market. For atumelnant, a treatment for CAH with a larger $1 billion market potential, Goldman highlights significant execution risk, including a projected 2028 launch that is three years behind a competitor and potential challenges in its pivotal Phase 3 studies. While the company exhibits a strong balance sheet, with a current ratio of 22.53 and a cash runway into 2029, this financial stability is contrasted by a reported decline in Q1 2025 revenue to $400,000 from $600,000 year-over-year. The significant divergence between Goldman's target and the more optimistic price targets from JMP Securities ($90) and H.C. Wainwright ($81) underscores the market's uncertainty, with CRNX's near-term valuation heavily dependent on the successful launch of paltusotine and the unfolding competitive landscape.

Key Decisions for Investors

• Investors should closely monitor the upcoming September 25 PDUFA date for paltusotine and its initial commercial launch metrics, as this is the primary near-term catalyst for the stock.
• Pay close attention to the launch performance of the competitor drug from Crenessity, as its market adoption and reimbursement trends will serve as a key proxy for the potential success of Crinetics' atumelnant.
• Given the significant disparity in analyst price targets, consider the current valuation in the context of both the company's robust cash position and the substantial clinical and commercial execution risks highlighted by Goldman Sachs.
• A neutral stance may be warranted until there is greater clarity on paltusotine's sales traction and the outcome of atumelnant's pivotal trials, reflecting the lack of other meaningful pipeline catalysts in the near future.